Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180

Lars H Engelholm; Eva Maria Carlsen Melander; Andreas Hald; Morten Persson; Daniel H Madsen; Henrik J Jürgensen; Kristina Johansson; Christoffer Nielsen; Kirstine S Nørregaard; Signe Z Ingvarsen; Andreas Kjaer; Clement S Trovik; Ole Didrik Lærum; Thomas H Bugge; Johan Eide; Niels Behrendt

doi:10.1002/path.4661

Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180

Lars H Engelholm, Eva Maria Carlsen Melander, Andreas Hald, Morten Persson, Daniel H Madsen, Henrik J Jürgensen, Kristina Johansson, Christoffer Nielsen, Kirstine S Nørregaard, Signe Z Ingvarsen, Andreas Kjaer, Clement S Trovik, Ole Didrik Lærum, Thomas H Bugge, Johan Eide, Niels Behrendt

Endocrinology and Metabolism

11 Citations (Scopus)

Abstract

In osteosarcoma, a primary mesenchymal bone cancer occurring predominantly in younger patients, invasive tumour growth leads to extensive bone destruction. This process is insufficiently understood, cannot be efficiently counteracted and calls for novel means of treatment. The endocytic collagen receptor, uPARAP/Endo180, is expressed on various mesenchymal cell types and is involved in bone matrix turnover during normal bone growth. Human osteosarcoma specimens showed strong expression of this receptor on tumour cells, along with the collagenolytic metalloprotease, MT1-MMP. In advanced tumours with ongoing bone degeneration, sarcoma cells positive for these proteins formed a contiguous layer aligned with the degradation zones. Remarkably, osteoclasts were scarce or absent from these regions and quantitative analysis revealed that this scarcity marked a strong contrast between osteosarcoma and bone metastases of carcinoma origin. This opened the possibility that sarcoma cells might directly mediate bone degeneration. To examine this question, we utilized a syngeneic, osteolytic bone tumour model with transplanted NCTC-2472 sarcoma cells in mice. When analysed in vitro, these cells were capable of degrading the protein component of surface-labelled bone slices in a process dependent on MMP activity and uPARAP/Endo180. Systemic treatment of the sarcoma-inoculated mice with a mouse monoclonal antibody that blocks murine uPARAP/Endo180 led to a strong reduction of bone destruction. Our findings identify sarcoma cell-resident uPARAP/Endo180 as a central player in the bone degeneration of advanced tumours, possibly following an osteoclast-mediated attack on bone in the early tumour stage. This points to uPARAP/Endo180 as a promising therapeutic target in osteosarcoma, with particular prospects for improved neoadjuvant therapy.

Original language	English
Journal	Journal of Pathology
Volume	238
Issue number	1
Pages (from-to)	120-33
Number of pages	14
ISSN	0022-3417
DOIs	https://doi.org/10.1002/path.4661
Publication status	Published - 1 Jan 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/path.4661

Cite this

Engelholm, L. H., Carlsen Melander, E. M., Hald, A., Persson, M., Madsen, D. H., Jürgensen, H. J., Johansson, K., Nielsen, C., Nørregaard, K. S., Ingvarsen, S. Z., Kjaer, A., Trovik, C. S., Lærum, O. D., Bugge, T. H., Eide, J., & Behrendt, N. (2016). Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180. Journal of Pathology, 238(1), 120-33. https://doi.org/10.1002/path.4661

Engelholm, LH, Carlsen Melander, EM, Hald, A, Persson, M, Madsen, DH, Jürgensen, HJ, Johansson, K, Nielsen, C , Nørregaard, KS , Ingvarsen, SZ , Kjaer, A, Trovik, CS, Lærum, OD, Bugge, TH, Eide, J & Behrendt, N 2016, 'Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180', Journal of Pathology, vol. 238, no. 1, pp. 120-33. https://doi.org/10.1002/path.4661

@article{e6707495ae884f31bc64d07b53178e4f,

title = "Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180",

abstract = "In osteosarcoma, a primary mesenchymal bone cancer occurring predominantly in younger patients, invasive tumour growth leads to extensive bone destruction. This process is insufficiently understood, cannot be efficiently counteracted and calls for novel means of treatment. The endocytic collagen receptor, uPARAP/Endo180, is expressed on various mesenchymal cell types and is involved in bone matrix turnover during normal bone growth. Human osteosarcoma specimens showed strong expression of this receptor on tumour cells, along with the collagenolytic metalloprotease, MT1-MMP. In advanced tumours with ongoing bone degeneration, sarcoma cells positive for these proteins formed a contiguous layer aligned with the degradation zones. Remarkably, osteoclasts were scarce or absent from these regions and quantitative analysis revealed that this scarcity marked a strong contrast between osteosarcoma and bone metastases of carcinoma origin. This opened the possibility that sarcoma cells might directly mediate bone degeneration. To examine this question, we utilized a syngeneic, osteolytic bone tumour model with transplanted NCTC-2472 sarcoma cells in mice. When analysed in vitro, these cells were capable of degrading the protein component of surface-labelled bone slices in a process dependent on MMP activity and uPARAP/Endo180. Systemic treatment of the sarcoma-inoculated mice with a mouse monoclonal antibody that blocks murine uPARAP/Endo180 led to a strong reduction of bone destruction. Our findings identify sarcoma cell-resident uPARAP/Endo180 as a central player in the bone degeneration of advanced tumours, possibly following an osteoclast-mediated attack on bone in the early tumour stage. This points to uPARAP/Endo180 as a promising therapeutic target in osteosarcoma, with particular prospects for improved neoadjuvant therapy.",

author = "Engelholm, {Lars H} and {Carlsen Melander}, {Eva Maria} and Andreas Hald and Morten Persson and Madsen, {Daniel H} and J{\"u}rgensen, {Henrik J} and Kristina Johansson and Christoffer Nielsen and N{\o}rregaard, {Kirstine S} and Ingvarsen, {Signe Z} and Andreas Kjaer and Trovik, {Clement S} and L{\ae}rum, {Ole Didrik} and Bugge, {Thomas H} and Johan Eide and Niels Behrendt",

note = "Copyright {\textcopyright} 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.",

year = "2016",

month = jan,

day = "1",

doi = "10.1002/path.4661",

language = "English",

volume = "238",

pages = "120--33",

journal = "Journal of Pathology",

issn = "0022-3417",

publisher = "JohnWiley & Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180

AU - Engelholm, Lars H

AU - Carlsen Melander, Eva Maria

AU - Hald, Andreas

AU - Persson, Morten

AU - Madsen, Daniel H

AU - Jürgensen, Henrik J

AU - Johansson, Kristina

AU - Nielsen, Christoffer

AU - Nørregaard, Kirstine S

AU - Ingvarsen, Signe Z

AU - Kjaer, Andreas

AU - Trovik, Clement S

AU - Lærum, Ole Didrik

AU - Bugge, Thomas H

AU - Eide, Johan

AU - Behrendt, Niels

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In osteosarcoma, a primary mesenchymal bone cancer occurring predominantly in younger patients, invasive tumour growth leads to extensive bone destruction. This process is insufficiently understood, cannot be efficiently counteracted and calls for novel means of treatment. The endocytic collagen receptor, uPARAP/Endo180, is expressed on various mesenchymal cell types and is involved in bone matrix turnover during normal bone growth. Human osteosarcoma specimens showed strong expression of this receptor on tumour cells, along with the collagenolytic metalloprotease, MT1-MMP. In advanced tumours with ongoing bone degeneration, sarcoma cells positive for these proteins formed a contiguous layer aligned with the degradation zones. Remarkably, osteoclasts were scarce or absent from these regions and quantitative analysis revealed that this scarcity marked a strong contrast between osteosarcoma and bone metastases of carcinoma origin. This opened the possibility that sarcoma cells might directly mediate bone degeneration. To examine this question, we utilized a syngeneic, osteolytic bone tumour model with transplanted NCTC-2472 sarcoma cells in mice. When analysed in vitro, these cells were capable of degrading the protein component of surface-labelled bone slices in a process dependent on MMP activity and uPARAP/Endo180. Systemic treatment of the sarcoma-inoculated mice with a mouse monoclonal antibody that blocks murine uPARAP/Endo180 led to a strong reduction of bone destruction. Our findings identify sarcoma cell-resident uPARAP/Endo180 as a central player in the bone degeneration of advanced tumours, possibly following an osteoclast-mediated attack on bone in the early tumour stage. This points to uPARAP/Endo180 as a promising therapeutic target in osteosarcoma, with particular prospects for improved neoadjuvant therapy.

AB - In osteosarcoma, a primary mesenchymal bone cancer occurring predominantly in younger patients, invasive tumour growth leads to extensive bone destruction. This process is insufficiently understood, cannot be efficiently counteracted and calls for novel means of treatment. The endocytic collagen receptor, uPARAP/Endo180, is expressed on various mesenchymal cell types and is involved in bone matrix turnover during normal bone growth. Human osteosarcoma specimens showed strong expression of this receptor on tumour cells, along with the collagenolytic metalloprotease, MT1-MMP. In advanced tumours with ongoing bone degeneration, sarcoma cells positive for these proteins formed a contiguous layer aligned with the degradation zones. Remarkably, osteoclasts were scarce or absent from these regions and quantitative analysis revealed that this scarcity marked a strong contrast between osteosarcoma and bone metastases of carcinoma origin. This opened the possibility that sarcoma cells might directly mediate bone degeneration. To examine this question, we utilized a syngeneic, osteolytic bone tumour model with transplanted NCTC-2472 sarcoma cells in mice. When analysed in vitro, these cells were capable of degrading the protein component of surface-labelled bone slices in a process dependent on MMP activity and uPARAP/Endo180. Systemic treatment of the sarcoma-inoculated mice with a mouse monoclonal antibody that blocks murine uPARAP/Endo180 led to a strong reduction of bone destruction. Our findings identify sarcoma cell-resident uPARAP/Endo180 as a central player in the bone degeneration of advanced tumours, possibly following an osteoclast-mediated attack on bone in the early tumour stage. This points to uPARAP/Endo180 as a promising therapeutic target in osteosarcoma, with particular prospects for improved neoadjuvant therapy.

U2 - 10.1002/path.4661

DO - 10.1002/path.4661

M3 - Journal article

C2 - 26466547

SN - 0022-3417

VL - 238

SP - 120

EP - 133

JO - Journal of Pathology

JF - Journal of Pathology

IS - 1

ER -

Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this